13 completed, 6 unknown, 5 terminated, 3 recruiting. 8 Phase 4, 6 Phase 1, 5 Phase 2, 4 Phase 3, 1 Early Phase 1.
Follow Hemophilia A With Inhibitor: new trials by email Literature Review of Hemophilia A With Inhibitor trials Research Report on Hemophilia A With Inhibitor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction efanesoctacog alpha, Emicizumab - Hemophilia A With Inhibitor | Phase 4 | Not yet recruiting | Versiti Blood Health | 15 | 2026-12-01 | 2026-07-27 |
| Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study) Advate® - Hemophilia a with Inhibitor | Phase 4 | Recruiting | Runhui WU | 110 | 2025-03-01 | 2025-03-07 |
| The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial SerpinPC - Hemophilia a, Hemophilia B | Phase 3 | Terminated | ApcinteX Ltd | 15 | 2024-07-11 | 2025-02-10 |
| Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem Thrombin generation assay (EnzySystem HemA version A - whole blood), Thrombin generation assay (Ceveron s100 (Technoclone) - fresh plasma), Additional coagulation tests - Hemophilia A With Inhibitor, Hemophilia A | Completed | Enzyre B.V. | 6 | 2024-03-26 | 2024-04-10 | |
| Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors KN057 - Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Phase 3 | Active not recruiting | Suzhou Alphamab Co., Ltd. | 53 | 2024-01-09 | 2025-09-17 |
| ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor SCT800 and Daratumumab, SCT800 - Hemophilia A With Inhibitor | Phase 4 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2023-11-22 | 2025-02-24 |
| SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment SS109 - Male, Hemophilia A With Inhibitor | Phase 1 / Phase 2 | Completed | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 24 | 2023-10-12 | 2024-07-19 |
| A Phase I of SS109 in Hemophilia A or and B With Inhibitors SS109 - Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Phase 1 | Completed | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 27 | 2022-12-14 | 2023-08-22 |
| Pharmacokinetic-guided Dosing of Emicizumab Emicizumab - PK-guided dose reduction, Emicizumab - Dosis continuation group, Emicizumab - Dose adjustment group - Hemophilia A With Inhibitor, Hemophilia A Without Inhibitor | Phase 4 | Unknown | Kathelijn Fischer | 95 | 2022-09-08 | 2024-03-20 |
| The Hemophilia Inhibitor Eradication Trial Eloctate ITI, Emicizumab - Hemophilia A With Inhibitor | Phase 3 | Terminated | Margaret Ragni | 1 | 2021-11-01 | 2023-02-21 |
| SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors coagulation factor VIIa [recombinant]-jncw - Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Phase 4 | Recruiting | American Thrombosis and Hemostasis Network | 55 | 2021-06-28 | 2026-01-12 |
| Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders Coagulation Factor VIIa variant - Factor VII Deficiency, Glanzmann Thrombasthenia | Phase 1 / Phase 2 | Terminated | Catalyst Biosciences | 19 | 2021-05-17 | 2021-12-21 |
| Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B MarzAA - Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Phase 3 | Terminated | Catalyst Biosciences | 18 | 2021-05-04 | 2021-12-17 |
| Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors Eptacog alfa, activated - Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Early Phase 1 | Completed | AryoGen Pharmed Co. | 14 | 2020-12-29 | 2022-09-10 |
| Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors Valoctocogene roxaparvovec - Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII | Phase 1 / Phase 2 | Completed | BioMarin Pharmaceutical | 10 | 2020-12-10 | 2026-07-10 |
| Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia. TQG203, TQG203/NovoSeven® - Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 24 | 2020-12-01 | 2021-02-24 |
| A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab Feiba - Hemophilia A With Inhibitor | Phase 4 | Active not recruiting | Children's Hospital Los Angeles | 20 | 2020-07-01 | 2022-03-09 |
| An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families Qualitative Interview - Hemophilia A With Inhibitor | Completed | Haemnet | 30 | 2020-02-28 | 2024-08-19 | |
| A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip PEGylated Liposome (PEGLip) - Hemophilia A With Inhibitor | Phase 2 | Unknown | Ascension Healthcare Development Limited | 20 | 2019-12-23 | 2021-10-21 |
| Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia MarzAA (marzeptacog alfa [activated]) - Hemophilia A, Hemophilia B | Phase 1 | Completed | Catalyst Biosciences | 11 | 2019-09-24 | 2021-09-13 |
Showing 20 of 30. Sign in to see all of them.
Hemophilia A (16) · Hemophilia B (4) · Factor VII Deficiency (3) · Thrombasthenia (2) · Blood Coagulation Disorders (1) · Blood Coagulation Disorders, Inherited (1) · Coagulation Protein Disorders (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemorrhage (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (19) · Hemic and Lymphatic Diseases (19) · Blood Coagulation Disorders (18) · Blood Coagulation Disorders, Inherited (18) · Coagulation Protein Disorders (18) · Genetic Diseases, Inborn (18) · Hematologic Diseases (18) · Hemorrhagic Disorders (18) · Genetic Diseases, X-Linked (4) · Blood Platelet Disorders (2) · Cardiovascular Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Vascular Diseases (1)
emicizumab (3) · Factor VIII (2) · factor VIII-Fc fusion protein (2) · Blood Specimen Collection (1) · Factor VII (1) · Factor VIIa (1) · Prednisone (1) · Protein C (1) · Rituximab (1) · Valoctocogene Roxaparvovec (1) · anti-inhibitor coagulant complex (1) · daratumumab (1) · marzeptacog alfa (activated) (1) · recombinant FVIIa (1) · simoctocog alfa (Nuwiq) (1)
Catalyst Biosciences (4) · American Thrombosis and Hemostasis Network (3) · AryoGen Pharmed Co. (2) · Hangzhou Gensciences Biopharmaceutical Co., Ltd. (2) · ApcinteX Ltd (1) · Ascension Healthcare Development Limited (1) · Beijing Children's Hospital (1) · BioMarin Pharmaceutical (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Children's Hospital Los Angeles (1) · Enzyre B.V. (1) · Haemnet (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · JW Pharmaceutical (1) · Kathelijn Fischer (1)
United States (10) · China (7) · Russia (5) · Georgia (3) · Italy (3) · Poland (3) · United Kingdom (3) · Armenia (2) · India (2) · Iran (2) · South Africa (2) · South Korea (2) · Taiwan (2) · Turkey (Türkiye) (2) · Ukraine (2)
Howard Levy, MD, PhD, MMM (2) · Renchi Yang (2) · Changcheng Zheng, Doctor (1) · Chenghao Jin, Doctor (1) · Chuhl Joo Lyu, Prof (1) · Courtney Thornburg, MD, MS (1) · Erik Berntorp, MD, PhD (1) · Guy Young, MD (1) · Hu Zhou, Doctor (1) · Jing Sun, Doctor (1) · Jingyu Yan, Doctor (1) · Lei Zhang (1) · Lili Chen, Doctor (1) · Margaret V Ragni, MD, MPH (1) · Marijke van den Berg, MD, PhD (1)
PMID 40286913, PMID 40289300, PMID 41220279, PMID 42382314
2019 (1), 2023 (1)